Evotec SE (NASDAQ: EVO) announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of its Supervisory Board at the company's Annual General Meeting scheduled for June 11, 2026.

The meeting agenda includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board and a proposal to expand the board from six to seven members.

The Hamburg-based life sciences company also entered into a cooperation agreement with MAK Capital Fund LP, a shareholder of Evotec. Under the agreement, MAK Capital committed to customary voting and cooperation provisions.

"We are pleased to nominate Wolfgang for election at the upcoming AGM," said Prof. Dr. Iris Löw-Friedrich, Chairwoman of Evotec's Supervisory Board. "His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise."

Michael A. Kaufman, Chief Executive Officer of MAK Capital, stated: "We appreciate the constructive dialogue and welcome Wolfgang's nomination to the Supervisory Board."

The nominations and board expansion require shareholder approval at the Annual General Meeting. Evotec operates as a drug discovery and development company with more than 4,500 employees across sites in Europe and the United States.